Clinical trials: Pharmacogenomics
Cardiotoxicity
Development of a Pharmacogenomic Panel for Early Detection of Chemotherapy- and Immunotherapy-Induced Cardiotoxicity.
To evaluate the use of a pharmacogenetic and pharmacoepigenetic panel for predicting chemotherapy- and immunotherapy-induced cardiotoxicity in cancer patients.
- Trial name
- NCT07663357
- Where
- 6 sites in Brazil
- Volunteers
- 1,000 people
- Sponsor
- Beneficência Portuguesa de São Paulo
Coronary Arterial Disease (CAD), ACS (Acute Coronary Syndrome)
Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients
The goal of this clinical trial is to learn if the pilot intervention of CYP2C19 genotype-guided antiplatelet therapy works to reduce the occurrence of cardiovascular events after Percutaneous Coronary Intervention (PCI) done in…
- Conditions
- Coronary Arterial Disease (CAD), ACS (Acute Coronary Syndrome), SCAD
- Trial name
- NCT06759272
- Testing
- CYP2C19 genotype-guided antiplatelet therapy
- Where
- Malaysia
- Volunteers
- 120 people
- Sponsor
- Nur Hafizah Annezah binti Utuh
Diabete Type 2, Pharmacogenomic Drug Interaction
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses
This research study aims to learn about how the body responds to food through different genetic pathways and how these responses may change during a short course of orforglipron.
- Trial name
- PATHS-T2D (NCT07739537)
- Testing
- Orforglipron
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Diabetes, Cholesterol
Interprofessional Pharmacogenomics (IPGx) Registry and Repository
This program collects genetic and health information to help doctors choose the right medications for patients.
- Conditions
- Diabetes, Cholesterol, Cancer, Blood Pressure Disorders
- Trial name
- IPGx Registry (NCT06726590)
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Texas A&M University
Stroke, Transient Ischemic Attack (TIA)
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic…
- Trial name
- CYP-FAST (NCT06943586)
- Testing
- CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Alabama at Birmingham
Cancer
Predictive Value of Drug Elimination Gene Polymorphisms on Clearance and Dose Adjustment of Sunitinib in Cancer Patients
Sunitinib is an anticancer drug, but like most drugs, the effect varies from person to person. This is partly due to a variation in how well each person eradicates the drug from the body.
- Trial name
- CLEARSUN (NCT01098903)
- Where
- 3 sites in Australia, Netherlands
- Volunteers
- 52 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Pharmacogenetics, Depression - Major Depressive Disorder
An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.
The goal of this prospective, randomized clinical trial is to learn whether pharmacogenomic (PGx)-guided comprehensive medication management delivered by pharmacists in community pharmacies will improve antidepressant treatment…
- Conditions
- Pharmacogenetics, Depression - Major Depressive Disorder, Pharmacogenomic Drug Interaction, Community Pharmacy Services
- Trial name
- COMPASS-PGx (NCT07373470)
- Testing
- Comprehensive medication management with PGx testing results, Usual Care
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- University of Pittsburgh
Polypharmacy
Effectiveness of PGx Testing
The purpose of this study is to determine the clinical and economic effectiveness of a pharmacogenomic (PGx) approach to prescribing medications in patients with high-risk polypharmacy in an integrated healthcare delivery system.
- Trial name
- NCT04120480
- Testing
- Pharmacogenomic test
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Kaiser Permanente
Pharmacogenomic Drug Interaction
PRE-EMPTIVE PHARMACOGENOMICS IN ACUTE CARE SETTINGS WITH HEALTH ECONOMIC EVALUATIONS (PHOENIX TRIAL)
It is known that individuals respond differently to the same medicine with some people benefitting, some experiencing no effect and others suffering side-effects or even coming to harm.
- Trial name
- PHOENIX (NCT06907784)
- Testing
- Pharmacogenomic testing
- Where
- 5 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- NHS Greater Glasgow and Clyde
Fungal Infection, Haematological Malignancy
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
This project aims to address invasive fungal infections in patients, by precision dosing of voriconazole based on CYP2C19 genotype testing with Bayesian dose-forecasting dosing software to develop patient-centric and maximally…
- Conditions
- Fungal Infection, Haematological Malignancy, Blood Cancer, Infectious Disease
- Trial name
- PRAGMATIC (NCT06510699)
- Testing
- genotype-directed dosing with dosing software based on therapeutic drug monitoring
- Where
- 7 sites in United States, Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- The University of Queensland
Medication Therapy Management, Pharmacogenomics
Implementation Study of Enhanced Medication Therapy Management in Primary Care Practice
The purpose of this study is to identify challenges and successes associated with implementing an enhanced medication therapy management service in primary care practice.
- Trial name
- EMTM (NCT02748148)
- Testing
- Medication therapy management
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Tabula Rasa HealthCare
Type 2 Diabetes, Cardiovascular Diseases
Genetic-Dependent Cardiovascular Response to PPAR-Alpha Agonist Fenofibrate
Fenofibrate, a peroxisome proliferator-activated receptor-alpha (PPAR-a) agonist known to improve diabetic dyslipidemia, has been proposed as a drug to prevent cardiovascular disease (CVD) in type 2 diabetes (T2D).
- Conditions
- Type 2 Diabetes, Cardiovascular Diseases, Pharmacogenomic Drug Interaction
- Trial name
- MAGNETIC (NCT05542147)
- Testing
- Fenofibrate 145 mg
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Mario Luca Morieri
Healthy Volunteers, Aerosol Therapy
Inhaled Dose Analysis Using a Breath Actuated Nebulizer in Healthy Subjects
The goal of this crossover study is to compare urine drug concentrations using a continuous vibrating mesh nebulizer versus a breath-actuated vibrating mesh nebulizer in healthy volunteers.
- Conditions
- Healthy Volunteers, Aerosol Therapy, Inhaled Drug Dose, Pharmacogenomic Drug Interaction
- Trial name
- NCT06157515
- Testing
- Breath-actuated vibrating mesh nebulizer, Continuous vibrating mesh nebulizer
- Where
- Taiwan
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Chang Gung University
Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases
Macular neovascular diseases including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), pathological myopia (PM) and etc. can cause severe vision loss.
- Conditions
- Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy, Pathological Myopia, Conbercept
- Trial name
- NCT03128463
- Testing
- Intravitreal injection of conbercept
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Xun Xu
Atrial Fibrillation, Deep Vein Thrombosis
Genotype-Guided Warfarin Therapy Trial
The purpose of the investigators' study is to determine the clinical utility of a warfarin-dosing algorithm that incorporates genetic information (VKORC1 and CYP2C9 alleles) for adult patients initiating warfarin therapy.
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Artificial Heart Valve
- Trial name
- WARFPGX (NCT00904293)
- Testing
- Genotype-guided dose determination, Non-genotype guided warfarin dosing
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- University of North Carolina, Chapel Hill
Heart Failure With Reduced Ejection Fraction
Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score
The purpose of this trial is to better understand how the beta-blocker metoprolol works in people with Heart Failure with Reduced Ejection Fraction (HFrEF) according to participants genetics.
- Trial name
- NCT07490067
- Testing
- Metoprolol Succinate, Beta-Blocker Polygenic Score, Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Michigan
Pharmacogenetics, Pharmacogenomic Drug Interaction
An Evaluation of the Impact of Pharmacist Personalized Medication Reviews With and Without a Discussion of Pharmacogenomic Results in an Employee Health Program.
The goal of this prospective randomized clinical trial is to learn if a pharmacist-provided personalized medication review (PMR) that discusses pharmacogenomic test results will improve medication outcomes.
- Trial name
- MyPGx (NCT06660264)
- Testing
- Pharmacist Personalized Medication Review (PMR), Discussion of Pharmacogenomic results during the PMR
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- University of Pittsburgh
Hypertension
Pharmacogenomic Evaluation of Antihypertensive Responses in Induced Pluripotent Stem (iPS) Cells Study
Patients enrolled in this study will have completed one of the parent studies "Pharmacogenomic Evaluation of Antihypertensive Responses" (PEAR-1 or PEAR-2) evaluating how well their blood pressure was controlled by medication.
- Trial name
- PEAR-iPSC (NCT01943383)
- Testing
- iPSC
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Florida
HIV Infections
Pharmacogenomic of Atazanavir/Efavirenz (ATV/EFV)
Objectives: To evaluate the impact of genetic polymorphism on ARV drug levels To evaluate the effect of genetic polymorphism/drug levels on long term immunologic and virologic response To correlate the genetic polymorphism/drug…
- Trial name
- NCT01138267
- Where
- Thailand
- Volunteers
- 450 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
This is a prospective phase II clinical study planned to be conducted at the Medical College of Wisconsin (MCW). After meeting the study criteria and enrollment, patients will be treated with a cladribine based salvage regimen…
- Trial name
- NCT03150004
- Testing
- Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Cladribine and Cytarabine (CLLDAC) Regimen
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Medical College of Wisconsin